Security
Prime Medicine, Inc. Common Stock · PRME
PRMENASDAQCommon stockCurrentCIK 1894562Updated Oct 6, 2026
PRME price & chart
Loading TradingView…
NASDAQ:PRME on TradingView ↗About the company
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
In the news
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 385,012,000Source | 332,784,000Source | 249,040,000Source | 279,009,000Source | 259,705,000Source | 294,730,000Source | 328,163,000Source | 311,383,000Source | 342,733,000Source | 297,508,000Source | 193,851,000Source | 360,314,000Source |
| Property, Plant and Equipment, NetUSD | 22,046,000Source | 23,287,000Source | 17,077,000Source | 23,828,000Source | 23,812,000Source | 18,816,000Source | 24,956,000Source | 23,926,000Source | 20,572,000Source | 24,404,000Source | 22,659,000Source | 19,009,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 71,396,000Source | 117,977,000Source | 47,451,000Source | 53,804,000Source | 55,600,000Source | 64,106,000Source | 91,877,000Source | 94,162,000Source | 63,032,000Source | 182,476,000Source | 41,574,000Source | 187,620,000Source |
| Assets, CurrentUSD | 231,406,000Source | 246,071,000Source | 96,804,000Source | 121,287,000Source | 170,803,000Source | 137,889,000Source | 163,765,000Source | 217,654,000Source | 181,293,000Source | 211,886,000Source | 142,976,000Source | 296,618,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 2,697,000Source |
| Operating Lease, Right-of-Use AssetUSD | 117,869,000Source | 49,364,000Source | 120,468,000Source | 120,203,000Source | 51,594,000Source | 123,334,000Source | 125,380,000Source | 55,528,000Source | 126,177,000Source | 47,156,000Source | 13,941,000Source | 29,545,000Source |
| Other Assets, NoncurrentUSD | — | 0Source | 1,000,000Source | — | 0Source | 1,000,000Source | — | 779,000Source | 1,000,000Source | 0Source | 779,000Source | 1,646,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 223,191,000Source | 143,280,000Source | 209,231,000Source | 218,149,000Source | 63,116,000Source | 218,030,000Source | 221,239,000Source | 67,617,000Source | 221,865,000Source | 144,359,000Source | 60,780,000Source | 44,044,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 1,004,061,000Source | 834,417,000Source | 1,019,401,000Source | 852,561,000Source | 789,076,000Source | 1,014,175,000Source | 846,039,000Source | 780,950,000Source | 1,009,138,000Source | 840,358,000Source | 624,414,000Source | 609,849,000Source |
| Retained Earnings (Accumulated Deficit)USD | -842,275,000Source | -644,936,000Source | -979,585,000Source | -791,693,000Source | -592,418,000Source | -937,476,000Source | -739,102,000Source | -537,091,000Source | -888,354,000Source | -687,212,000Source | -491,330,000Source | -293,197,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 33,000Source | 21,000Source | -9,000Source | -10,000Source | -71,000Source | -1,000Source | -15,000Source | -95,000Source | 82,000Source | 1,000Source | -15,000Source | -384,000Source |
| Stockholders' Equity Attributable to ParentUSD | 161,821,000Source | 189,504,000Source | 39,809,000Source | 60,860,000Source | 196,589,000Source | 76,700,000Source | 106,924,000Source | 243,766,000Source | 120,868,000Source | 153,149,000Source | 133,071,000Source | 316,270,000Source |
| Liabilities and EquityUSD | 385,012,000Source | 332,784,000Source | 249,040,000Source | 279,009,000Source | 259,705,000Source | 294,730,000Source | 328,163,000Source | 311,383,000Source | 342,733,000Source | 297,508,000Source | 193,851,000Source | 360,314,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 35,019,000Source | 37,877,000Source | 31,692,000Source | 34,109,000Source | 20,749,000Source | 36,289,000Source | 34,288,000Source | 24,441,000Source | 37,448,000Source | 37,961,000Source | 56,423,000Source | 26,714,000Source |
| Operating Lease, Liability, CurrentUSD | 7,714,000Source | 4,484,000Source | 8,972,000Source | 7,258,000Source | 5,216,000Source | 8,546,000Source | 6,858,000Source | 6,751,000Source | 8,137,000Source | 3,614,000Source | 9,276,000Source | 11,694,000Source |
| Accounts Payable, CurrentUSD | 9,354,000Source | 5,429,000Source | 5,808,000Source | 6,378,000Source | 4,638,000Source | 12,325,000Source | 10,025,000Source | 10,078,000Source | 8,887,000Source | 11,351,000Source | 19,537,000Source | 4,332,000Source |
| Operating Lease, Liability, NoncurrentUSD | 110,421,000Source | 36,764,000Source | 103,506,000Source | 112,478,000Source | 36,367,000Source | 105,966,000Source | 114,293,000Source | 37,042,000Source | 108,290,000Source | 37,180,000Source | 4,357,000Source | 17,051,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | 134,000Source | — | — | 0Source | 279,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 11,000,000Source | 18,684,000Source | 8,978,000Source | 12,158,000Source | 10,895,000Source | 8,098,000Source | 9,191,000Source | 7,612,000Source | 12,600,000Source | 15,904,000Source | 14,110,000Source | 10,688,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 213,300,000Source | 175,500,000Source | 95,100,000Source | 101,800,000Source | 162,900,000Source | 135,500,000Source | 144,300,000Source | 210,700,000Source | 177,700,000Source | 190,400,000Source | 121,700,000Source | 293,900,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 279,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 1,881,000Source | 1,558,000Source | 1,785,000Source | 1,864,000Source | 1,856,000Source | 1,700,000Source | 7,321,000Source | 6,128,000Source | 4,653,000Source | 2,224,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,644,000Source | 5,681,000Source | 29,268,000Source | 26,068,000Source | 13,910,000Source | 6,459,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,552,000Source | 1,884,000Source | 996,000Source | -5,257,000Source | 9,140,000Source | 2,458,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 0Source | — | 0Source | -279,000Source | -964,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -42,710,000Source | -48,857,000Source | -162,564,000Source | -122,865,000Source | -165,412,000Source | -131,827,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 43,391,000Source | -47,742,000Source | -108,763,000Source | 68,457,000Source | 18,711,000Source | -47,096,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 214,000Source | 2,422,000Source | 4,531,000Source | 7,294,000Source | 8,724,000Source | 16,095,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 393,000Source | 6,000,000Source | 151,512,000Source | 195,876,000Source | 655,000Source | 181,494,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,074,000Source | -90,599,000Source | -119,815,000Source | 141,468,000Source | -146,046,000Source | 2,571,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 85,087,000Source | 132,039,000Source | 61,142,000Source | 67,495,000Source | 77,797,000Source | 105,939,000Source | 76,723,000Source | 196,538,000Source | 55,070,000Source | 201,116,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 12,747,000Source | 6,827,000Source | 4,865,000Source | 6,325,000Source | 4,644,000Source | 5,681,000Source | 29,268,000Source | 26,068,000Source | 13,910,000Source | 6,459,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 213,300,000Source | 175,500,000Source | 95,100,000Source | 101,800,000Source | 135,500,000Source | 144,300,000Source | 177,700,000Source | 190,400,000Source | 121,700,000Source | 293,900,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | -28,000Source | -8,000Source |
| General and Administrative ExpenseUSD | — | — | 11,208,000Source | 14,101,000Source | 11,042,000Source | 13,117,000Source | 17,405,000Source | 13,284,000Source | 52,346,000Source | 50,161,000Source | 43,387,000Source | 29,819,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source | -279,000Source | -948,000Source |
| Investment Income, InterestUSD | — | — | 1,141,000Source | 697,000Source | 788,000Source | 743,000Source | 1,021,000Source | 1,182,000Source | 4,149,000Source | 3,522,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -50,582,000Source | -52,518,000Source | -42,109,000Source | -52,591,000Source | -49,122,000Source | -51,890,000Source | -201,142,000Source | -195,882,000Source | -198,133,000Source | -121,821,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -50,582,000Source | -52,518,000Source | -42,109,000Source | -52,591,000Source | -49,122,000Source | -51,890,000Source | -201,142,000Source | -195,882,000Source | -198,133,000Source | -142,014,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,391,000Source | 1,714,000Source | 1,176,000Source | 786,000Source | 1,532,000Source | 502,000Source | 7,208,000Source | 6,585,000Source | 6,380,000Source | -6,225,000Source |
| Operating ExpensesUSD | — | — | 55,198,000Source | 54,441,000Source | 44,439,000Source | 54,492,000Source | 51,510,000Source | 53,846,000Source | 212,982,000Source | 205,450,000Source | 204,792,000Source | 116,544,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 44,000Source | -83,000Source | 55,000Source | 18,000Source | 51,000Source | 37,000Source | 148,000Source | 41,000Source | 8,762,000Source | 1,903,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 38,081,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 393,000Source | 0Source | 781,000Source | 103,000Source | 655,000Source | 219,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 357,000Source |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,225,000Source | 209,000Source | — | 1,115,000Source | — | 1,454,000Source | 4,632,000Source | 2,983,000Source | — | 0Source |
| Operating Income (Loss)USD | — | — | -53,973,000Source | -54,232,000Source | -43,285,000Source | -53,377,000Source | -50,654,000Source | -52,392,000Source | -208,350,000Source | -202,467,000Source | -204,792,000Source | -116,544,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 44,000Source | -83,000Source | 55,000Source | 18,000Source | 51,000Source | 37,000Source | 148,000Source | 41,000Source | 8,762,000Source | 1,903,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source | -279,000Source | -948,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -50,582,000Source | -52,518,000Source | -42,109,000Source | -52,591,000Source | -49,122,000Source | -51,890,000Source | -201,142,000Source | -195,882,000Source | -198,133,000Source | -121,821,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.32Source | -0.44Source | -0.24Source | -0.41Source | -0.28Source | -0.4Source | -1.35Source | -1.65Source | -2.18Source | -4.19Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.32Source | -0.44Source | -0.24Source | -0.41Source | -0.28Source | -0.4Source | -1.35Source | -1.65Source | -2.18Source | -4.19Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 160,503,183Source | 119,764,270Source | 177,224,892Source | 129,185,918Source | 177,096,225Source | 130,884,490Source | 148,758,527Source | 118,600,381Source | 90,969,327Source | 33,891,264Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 160,503,183Source | 119,764,270Source | 177,224,892Source | 129,185,918Source | 177,096,225Source | 130,884,490Source | 148,758,527Source | 118,600,381Source | 90,969,327Source | 33,891,264Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 16,000Source |
| General and Administrative ExpenseUSD | — | — | 11,208,000Source | 14,101,000Source | 11,042,000Source | 13,117,000Source | 17,405,000Source | 13,284,000Source | 52,346,000Source | 50,161,000Source | 43,387,000Source | 29,819,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | -52,518,000Source | — | -52,591,000Source | — | -51,890,000Source | — | -195,882,000Source | -198,412,000Source | -122,769,000Source |
| Investment Income, InterestUSD | — | — | 1,141,000Source | 697,000Source | 788,000Source | 743,000Source | 1,021,000Source | 1,182,000Source | 4,149,000Source | 3,522,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -50,582,000Source | -52,518,000Source | -42,109,000Source | -52,591,000Source | -49,122,000Source | -51,890,000Source | -201,142,000Source | -195,882,000Source | -198,133,000Source | -142,014,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,391,000Source | 1,714,000Source | 1,176,000Source | 786,000Source | 1,532,000Source | 502,000Source | 7,208,000Source | 6,585,000Source | 6,380,000Source | -6,225,000Source |
| Operating ExpensesUSD | — | — | 55,198,000Source | 54,441,000Source | 44,439,000Source | 54,492,000Source | 51,510,000Source | 53,846,000Source | 212,982,000Source | 205,450,000Source | 204,792,000Source | 116,544,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 20,193,000Source |
| Research and Development ExpenseUSD | — | — | 43,990,000Source | 40,340,000Source | 33,397,000Source | 41,375,000Source | 34,105,000Source | 40,562,000Source | 160,636,000Source | 155,289,000Source | 147,905,000Source | 86,725,000Source |
Offerings
Registration 333-291348
Filing attachments
d863812dex991.htm · 8-K · 2025-05-19
EX-99.1 2 d863812dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease - First ever clinical data supporting safety and efficacy of Prime Editing in humans - - Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above …
Read attachment ↗d863812dex992.htm · 8-K · 2025-05-19
EX-99.2 3 d863812dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology - - On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 20…
Read attachment ↗d908678dex991.htm · 8-K · 2025-03-18
EX-99.1 2 d908678dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Delivering on the promise of Prime Editing Corporate Presentation March 2025 1 Forward Looking Statements This presentation contains forward-looking statements of Prime Medicine, Inc. ( Prime, we or our ) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements contain information about our current and future prospects and our operations, which are based on currently ava…
Read attachment ↗